If you made any changes in Pure these will be visible here soon.

Research Output 1995 2019

2019
2 Citations (Scopus)

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032
Open Access
L-Lactate Dehydrogenase
Monoclonal Antibodies
CD274 Antigen
Area Under Curve
Neoplasms
2 Citations (Scopus)

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis

Galli, G., Cavalieri, S., Di Guardo, L., Cimminiello, C., Nichetti, F., Corti, F., Garcia, M. A., Pappalardi, B., Fallai, C., De Braud, F., Platania, M. & Del Vecchio, M., Apr 1 2019, In : Oncology Research and Treatment. 42, 4, p. 182-188 7 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Radiotherapy
Brain
Survival

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Melanoma
Placebos
Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
Transaminases

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Jan 1 2019, (Accepted/In press) In : Tumori.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Lymphocyte Count
L-Lactate Dehydrogenase
Survival

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, S., Hinshelwood, R., Mesnage, S., Cebon, J., Ferrucci, P. F., Aglietta, M., Neyns, B., Chiarion-Sileni, V., Lindsay, C. R., Del Vecchio, M., Linardou, H., Merelli, B., Tonini, G., Atkinson, V., Freivogel, K., Stein, D., Dalland, L., Lau, M., Legenne, P., Queirolo, P. & 1 others, Millward, M., 2019, In : Melanoma Research. 29, 5, p. 527-532 6 p.

Research output: Contribution to journalArticle

Melanoma
Confidence Intervals
Therapeutics
Disease-Free Survival
Fever
11 Citations (Scopus)

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Feb 13 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 2, p. 511-521 11 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Survival
Vitiligo
Programmed Cell Death 1 Receptor
Open Access
Immunotherapy
Melanoma
CTLA-4 Antigen
Cell Death
Vulva

Pembrolizumab in the treatment of advanced/metastatic melanoma: A single-center institution experience

Cimminiello, C., Indini, A., Di Guardo, L., Prisciandaro, M., Randon, G., Tolomio, E., De Braud, F. & Del Vecchio, M., Jun 1 2019, In : Melanoma Research. 29, 3, p. 289-294 6 p.

Research output: Contribution to journalArticle

Melanoma
Confidence Intervals
Therapeutics
Proportional Hazards Models
Disease-Free Survival
Tissue Distribution
Melanoma
Catenins
Myeloid Cells
Immunity
2018

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma

Mennini, F. S., Bini, C., Marcellusi, A. & Del Vecchio, M., Oct 2018, In : Clinical Drug Investigation. 38, 10, p. 967-976 10 p.

Research output: Contribution to journalReview article

Melanoma
Costs and Cost Analysis
Therapeutics
Investigational Therapies
Cost of Illness

Cutaneous melanoma in adolescents and young adults

Indini, A., Brecht, I., Del Vecchio, M., Sultan, I., Signoroni, S. & Ferrari, A., Nov 2018, In : Pediatric Blood and Cancer. 65, 11, p. e27292

Research output: Contribution to journalReview article

Young Adult
Melanoma
Skin
Therapeutics
Age Groups

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

De Santis, F., Del Vecchio, M., Castagnoli, L., De Braud, F., Di Cosimo, S., Franceschini, D., Fucà, G., Hiscott, J., Malmberg, K. J., McGranahan, N., Pietrantonio, F., Rivoltini, L., Sangaletti, S., Tagliabue, E., Tripodo, C., Vernieri, C., Zitvogel, L., Pupa, S. M. & Di Nicola, M., Dec 2018, In : Cytokine and Growth Factor Reviews. 44, p. 1-10 10 p.

Research output: Contribution to journalArticle

Investigational Therapies
Tumors
Monoclonal Antibodies
Neoplasms
Cells
2017
466 Citations (Scopus)

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J. J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 15 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J., Ascierto, P. A. & for the CheckMate 238 Collaborators, Nov 9 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

Melanoma
Recurrence
Poisons
Confidence Intervals
Therapeutics
466 Citations (Scopus)

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 14 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J. & Ascierto, P. A., 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

466 Citations (Scopus)

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 14 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J. & Ascierto, P. A., Nov 9 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

Melanoma
Recurrence
Confidence Intervals
Survival
Poisons
466 Citations (Scopus)

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 15 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J., Ascierto, P. A. & Guidoboni, M., 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

111 Citations (Scopus)

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., Thomas, L., Demidov, L., Garbe, C., Hogg, D., Liszkay, G., Queirolo, P., Wasserman, E., Ford, J., Weill, M., Sirulnik, L. A. & 4 others, Jehl, V., Bozón, V., Long, G. V. & Flaherty, K., Apr 2017, In : The Lancet Oncology. 18, 4, p. 435-445 11 p.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Immunotherapy
Disease-Free Survival
Safety
111 Citations (Scopus)

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., Thomas, L., Demidov, L., Garbe, C., Hogg, D., Liszkay, G., Queirolo, P., Wasserman, E., Ford, J., Weill, M., Sirulnik, L. A. & 4 others, Jehl, V., Bozón, V., Long, G. V. & Flaherty, K., 2017, In : The Lancet Oncology. 18, 4, p. 435-445 11 p.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Immunotherapy
Disease-Free Survival
Safety
135 Citations (Scopus)

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Davies, M. A., Saiag, P., Robert, C., Grob, J. J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., Moschos, S. J., Hogg, D., Márquez-Rodas, I., Del Vecchio, M., Lebbé, C., Meyer, N., Zhang, Y., Huang, Y., Mookerjee, B. & Long, G. V., Jul 1 2017, In : The Lancet Oncology. 18, 7, p. 863-873 11 p.

Research output: Contribution to journalArticle

Melanoma
Neoplasm Metastasis
Brain
dabrafenib
trametinib
135 Citations (Scopus)

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Davies, M. A., Saiag, P., Robert, C., Grob, J-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., Moschos, S. J., Hogg, D., Márquez-Rodas, I., Del Vecchio, M., Lebbé, C., Meyer, N., Zhang, Y., Huang, Y., Mookerjee, B. & Long, G. V., 2017, In : The Lancet Oncology. 18, 7, p. 863-873 11 p.

Research output: Contribution to journalArticle

2 Citations (Scopus)

Innovative Therapy, Monoclonal Antibodies and Beyond

Di Nicola, M., Apetoh, L., Bellone, M., Colombo, M. P., Dotti, G., Ferrone, S., Muscolini, M., Hiscott, J., Anichini, A., Pupa, S. M., Braud, F. D. & Del Vecchio, M., Dec 1 2017, In : Cytokine and Growth Factor Reviews. 38, p. 1-9 9 p.

Research output: Contribution to journalShort survey

Investigational Therapies
Immunotherapy
Tumors
T-cells
Monoclonal Antibodies
122 Citations (Scopus)

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 10 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A. & Maio, M., May 2017, In : The Lancet Oncology. 18, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

Melanoma
Therapeutics
Survival
ipilimumab
Colitis
122 Citations (Scopus)

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 10 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A. & Maio, M., 2017, In : The Lancet Oncology. 18, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

122 Citations (Scopus)

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 11 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A., Maio, M. & Guidoboni, M., 2017, In : The Lancet Oncology. 18, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

14 Citations (Scopus)

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Blank, C. U., Larkin, J., Arance, A. M., Hauschild, A., Queirolo, P., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Garbe, C., Chiarion Sileni, V., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G. A. P., Miller, W. H., Robson, S., Makrutzki, M., Antic, V. & 1 others, Brown, M. P., Jul 2017, In : European Journal of Cancer. 79, p. 176-184 9 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
Proto-Oncogene Proteins B-raf
14 Citations (Scopus)

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma

Blank, C. U., Larkin, J., Arance, A. M., Hauschild, A., Queirolo, P., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Garbe, C., Chiarion Sileni, V., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G. A. P., Miller, W. H., Robson, S., Makrutzki, M., Antic, V. & 1 others, Brown, M. P., Jul 2017, In : European Journal of Cancer. 79, p. 176-184 9 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
Proto-Oncogene Proteins B-raf
2 Citations (Scopus)
Melanoma
Radiotherapy
Neoplasm Metastasis
Disease-Free Survival
Survival
2016

Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Translated title of the contribution: AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumabDel Vecchio, M., Aug 2016, In : Recenti Progressi in Medicina. 107, 8, p. 414-7 4 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Survival Rate
Safety
Natural History
115 Citations (Scopus)

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Melanoma
Neutrophils
Lymphocytes
ipilimumab
Confidence Intervals

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Melanoma
Neutrophils
Lymphocytes
ipilimumab
Confidence Intervals

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Melanoma
Neutrophils
Lymphocytes
ipilimumab
Confidence Intervals

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Melanoma
Neutrophils
Lymphocytes
ipilimumab
Confidence Intervals

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Melanoma
Neutrophils
Lymphocytes
ipilimumab
Confidence Intervals
3 Citations (Scopus)

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: The INT Milan experience

Cavalieri, S., Di Guardo, L., Cimminiello, C., Bono, A., Tolomio, E., Colombetti, A., Valeri, B., Di Tolla, G., De Braud, F. & Del Vecchio, M., Sep 1 2016, In : Tumori. 102, 5, p. 501-507 7 p.

Research output: Contribution to journalArticle

Melanoma
Therapeutics
Disease Progression
Literature
Arthralgia

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., Curvietto, M., Del Vecchio, M., Bruzzi, P. & Ascierto, P. A., Jul 13 2016, In : Oncotarget.

Research output: Contribution to journalArticle

fotemustine
Melanoma
PLX4032
Therapeutics
Survival

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.

Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., Curvietto, M., Del Vecchio, M., Bruzzi, P. & Ascierto, P. A., Jul 1 2016, In : Oncotarget.

Research output: Contribution to journalArticle

8 Citations (Scopus)
Italy
Melanoma
Neutrophils
Lymphocytes
ipilimumab
16 Citations (Scopus)
Phosphatidylinositol 3-Kinases
Melanoma
Apoptosis
Phenotype
Effector Caspases
Immunotherapy
Melanoma
Radiotherapy
Neoplasm Metastasis
Brain
18 Citations (Scopus)
Immunotherapy
Melanoma
Radiotherapy
Neoplasm Metastasis
Brain
2015
22 Citations (Scopus)

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

Dugo, M., Nicolini, G., Tragni, G., Bersani, I., Tomassetti, A., Colonna, V., Vecchio, M. D., Braud, F. D., Canevari, S., Anichini, A. & Sensi, M., 2015, In : Oncotarget. 6, 7, p. 5118-5133 16 p.

Research output: Contribution to journalArticle

Receptor Protein-Tyrosine Kinases
Melanoma
Genes
Neoplasms
Phosphatidylinositol 3-Kinases
23 Citations (Scopus)

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J. J., Kendra, K., Agarwala, S. S., Li, M., Clawson, A., Brachmann, C., Karnoub, M. & 3 others, Elias, I., Renschler, M. F. & Hauschild, A., Nov 1 2015, In : Annals of Oncology. 26, 11, p. 2267-2274 8 p., mdv324.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Drug Therapy
Disease-Free Survival
Confidence Intervals
67 Citations (Scopus)

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study

Di Giacomo, A. M., Ascierto, P. A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G. & 1 others, Maio, M., Apr 1 2015, In : Annals of Oncology. 26, 4, p. 798-803 6 p.

Research output: Contribution to journalArticle

fotemustine
Biological Therapy
Melanoma
Neoplasms
Neoplasm Metastasis